Related Experiment Video
Updated: Aug 26, 2025

Author Spotlight: Advancements in Molecular Biomarker Testing for Non-Squamous Non-Small Cell Lung Cancer
Published on: September 8, 2023
Racial Diversity and Reporting in United States Food and Drug Administration Registration Trials for Thoracic
Ryan S Chiang1, Aakash Desai2, Michael J Glover1
1Department of Medicine, Stanford University, Stanford, CA, USA.
Abstract:
There is significant racial disparity in thoracic malignancies in terms of epidemiology and outcomes. We analyzed race reporting and racial diversity in the registration trials of drugs approved by the FDA for thoracic malignancies from 2006 to 2020. We found a significant under-representation of non-white participants in FDA drug registration trials in thoracic malignancies. Furthermore, though almost all trials report some race information, FDA guidelines are not universally followed. There is a disproportionate disease burden of lung cancer in under-represented race communities, and clinical trials should prioritize racial diversity and inclusion efforts.
More Related Videos
Related Concept Videos
Clinical Trials: Overview
Clinical Trials
There are four phases in a clinical trial. A phase one...
Hazard Ratio
For example, in a clinical trial...
Treatment Resistant Cancers
Cancer Survival Analysis

